Astellas Pharma, a global pharmaceutical company with cutting-edge capabilities in drug development, wishes to engage with academic research and biopharma companies and assets that involve the use of in vivo direct reprogramming to achieve cell conversion/ transdifferentiation from one cell type to another functional type.
Astellas is particularly interested in the direct reprogramming of cells to cell types related to the Central Nervous System, Lung, Heart, Kidney, Liver, Gut, Skin and Eye. Their goal is to discover therapeutic interventions that cure...